- Home
- UGI vs JAZZ Comparison
UGI vs JAZZ Comparison
Compare UGI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- JAZZ
- Stock Information
- Founded
- UGI 1940
- JAZZ 2003
- Country
- UGI United States
- JAZZ Ireland
- Employees
- UGI N/A
- JAZZ N/A
- Industry
- UGI Natural Gas Distribution
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- JAZZ Health Care
- Exchange
- UGI Nasdaq
- JAZZ Nasdaq
- Market Cap
- UGI 7.7B
- JAZZ 6.7B
- IPO Year
- UGI N/A
- JAZZ 2007
- Fundamental
- Price
- UGI $36.33
- JAZZ $112.87
- Analyst Decision
- UGI Buy
- JAZZ Strong Buy
- Analyst Count
- UGI 3
- JAZZ 12
- Target Price
- UGI $31.33
- JAZZ $183.08
- AVG Volume (30 Days)
- UGI 1.8M
- JAZZ 686.4K
- Earning Date
- UGI 08-06-2025
- JAZZ 07-30-2025
- Dividend Yield
- UGI 4.14%
- JAZZ N/A
- EPS Growth
- UGI N/A
- JAZZ 49.21
- EPS
- UGI 2.46
- JAZZ 7.51
- Revenue
- UGI $7,318,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- UGI $6.56
- JAZZ $6.00
- Revenue Next Year
- UGI $8.97
- JAZZ $4.85
- P/E Ratio
- UGI $14.69
- JAZZ $15.04
- Revenue Growth
- UGI N/A
- JAZZ 5.76
- 52 Week Low
- UGI $23.09
- JAZZ $95.49
- 52 Week High
- UGI $36.74
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- UGI 56.94
- JAZZ 55.60
- Support Level
- UGI $35.51
- JAZZ $109.27
- Resistance Level
- UGI $36.59
- JAZZ $116.77
- Average True Range (ATR)
- UGI 0.63
- JAZZ 2.80
- MACD
- UGI 0.03
- JAZZ 0.59
- Stochastic Oscillator
- UGI 86.87
- JAZZ 66.12
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.